Combination of endogenous pro-opiomelanocortin peptides is combination of the adrenocorticotropic hormone ACTH 1-13 and metenkefalin. The invention is a therapy to substitute corticosteroids, in the disease relapse and at determining the dose level and dynamics, but free of corticosteroid side effects. Changing the peptide combination dose and formula by at least doubling one of the components, in particular the ACTH 1-13, has resulted in successful substitution, so that the combination can be used in treating disease seizures. Therefore determined are gradually increased doses, adequate to the patient's disease gravity. In patients with high degrees of disability and disease, and aimed to decreasing the drug application dynamics, depot dose is applied. Nasal application is the shortest and the quickest route to the CNS, enabling the drug to be applied, instead of by injection that most patients are afraid of, as nasal spray, as a new way of application with a nasal application set, by atomising the active substances, that is, the POMC peptides, and their application as a spray. The invention is applied in treating of patients with disease relapse, chronic inflammatory and allergic diseases, especially autoimmune diseases, in treating and decreasing of discomforts in the patients with grave conditions of multiple sclerosis.La présente invention concerne une combinaison de peptides endogènes de type pro-opiomélanocortine et d'hormone adrénocorticotropique (ACTH 1-13) et de métenkéfaline. L'invention consiste, donc, en un traitement pouvant se substituer aux corticostéroïdes, en cas de rechute de la maladie et pour déterminer le niveau de dose et la dynamique, mais qui est dépourvu des effets secondaires des corticostéroïdes. La modification des doses et de la formulation de ladite combinaison de peptides consistant à au moins doubler la quantité d'un des composants et, notamment de l'ACTH 1-13, a permis l'obtention d'un substitut particulièrement efficace, si bien qu
